Financial Performance - The company's operating revenue for 2023 was ¥1,003,376,637.04, representing a 14.92% increase compared to ¥873,103,022.86 in 2022[21]. - The net profit attributable to shareholders decreased by 32.89% to ¥27,659,463.93 from ¥41,217,518.38 in the previous year[21]. - The net cash flow from operating activities dropped significantly by 69.58% to ¥47,414,104.46, down from ¥155,887,751.05 in 2022[21]. - Basic earnings per share fell by 42.86% to ¥0.04, compared to ¥0.07 in the previous year[21]. - Total assets increased by 27.22% to ¥2,133,478,855.05 from ¥1,677,058,446.16 at the end of 2022[21]. - The weighted average return on net assets decreased to 2.72% from 4.15% in 2022, a decline of 1.43%[21]. - The net profit after deducting non-recurring gains and losses was ¥35,421,382.66, a decrease of 7.36% from ¥38,235,775.09 in 2022[21]. - The company's net assets attributable to shareholders increased by 3.00% to ¥1,033,194,655.74 from ¥1,003,077,682.29 at the end of 2022[21]. Dividend Distribution - The company plans to distribute a cash dividend of ¥0.1 per 10 shares, totaling approximately ¥623,719.36 based on 623,719,364 shares[5]. - The company provided cash dividends of 0.10 yuan per 10 shares, totaling 6,237,193.64 yuan, which represents 100% of the profit distribution[150]. - The company plans to distribute dividends based on a total share capital of 623,719,364 shares after deducting restricted shares[151]. - The company has no plans for stock dividends, maintaining a focus on cash distribution to shareholders[151]. Market and Industry Trends - The pharmaceutical industry faced a challenging environment in 2023, with a reported 4% decline in revenue and a 16.2% drop in profit for large-scale pharmaceutical enterprises[30]. - The proportion of loss-making enterprises in the pharmaceutical sector increased to 24.7% in 2023, highlighting the competitive pressures within the industry[30]. - The company plans to expand its market presence in the traditional Chinese medicine sector, which has shown resilience with a revenue growth of 6.5% in 2023[30]. - The health drink business, primarily involving packaged drinking water, is experiencing stable growth, with a projected increase in per capita consumption from 36.95 liters in 2022 to 45.8 liters by 2025 in China[32]. - The steel structure industry is expected to see a processing volume of approximately 107 million tons in 2023, representing a year-on-year growth of about 6.4%[32]. Research and Development - The company is focusing on enhancing its R&D capabilities in response to the government's push for innovation in the pharmaceutical sector, particularly in traditional Chinese medicine[31]. - Research and development expenses rose by 26.71% to ¥31,902,380.11, reflecting increased investment in traditional Chinese medicine and generic drug development[63]. - The company holds 189 patent applications, with 163 granted, including 4 international invention patents, showcasing its strong commitment to innovation and technology development[43]. - The company is focusing on the development of new products, including the clinical application of traditional Chinese medicine and the expansion of its product pipeline[65]. - The company aims to enhance its market competitiveness through the internationalization of its products and the establishment of a strong brand in traditional Chinese medicine[65]. Acquisitions and Investments - The company acquired 70% equity in Shandong Lingkai and 51% equity in Tibet Kangyu, enhancing its market position and production capabilities[48]. - The company completed the acquisition of 70% equity in Shandong Lingkai Pharmaceutical and 51% equity in Tibet Kangyu Pharmaceutical, both of which are now included in the consolidated financial statements[166]. - The company is strategically expanding its market presence through acquisitions, including the recent stake in Xizang Kangyu Pharmaceutical Co., Ltd.[86]. Operational Efficiency - The company has established a comprehensive production quality control system, integrating advanced technologies such as near-infrared online quality monitoring, ensuring the stability of product quality[44]. - The company achieved a 100% pass rate in both internal inspections and external sampling for product quality during the reporting period[50]. - The company is enhancing its project management and incentive mechanisms to improve operational efficiency and adaptability to market changes[95]. - The company is implementing measures to manage raw material costs and mitigate supply risks through strategic procurement and inventory management[98]. Environmental Responsibility - The company strictly adheres to multiple environmental protection laws and standards, ensuring compliance with regulations[172]. - The company has obtained pollution discharge permits and conducts environmental protection management in accordance with legal requirements[173]. - The company reported a total nitrogen discharge of 11.77 mg/L, which is below the regulatory limit of 70 mg/L[174]. - The company has received recognition as a "Good Environmental Enterprise" by the Sichuan Provincial Department of Ecology and Environment for multiple years, including 2022[183]. - The company invested approximately CNY 1.44 million in environmental protection, focusing on wastewater treatment and air pollution control upgrades[181]. Governance and Management - The company has a complete and independent internal management structure, allowing it to exercise management authority independently[115]. - The company is committed to transparency and regular updates regarding its financial performance and strategic direction[119]. - The company has established a rigorous audit committee to oversee compliance and governance in its financial reporting[140]. - The company is focusing on enhancing its governance structure by ensuring a diverse and experienced board[120]. - The company has actively adopted suggestions from directors to improve its supervisory mechanisms[138]. Future Outlook - The company aims to achieve a net profit growth rate of 80% for 2021 and 30% for 2022, based on 2020 performance[157]. - Future guidance indicates a projected revenue growth of 18% for 2024, aiming for CNY 1.42 billion[132]. - The company plans to continue enhancing its internal control and governance practices based on the audit committee's recommendations[139]. - The company is actively engaging in discussions regarding future growth strategies and operational improvements[141].

Financial Performance - The company's revenue for Q1 2024 was ¥179,277,340.12, a decrease of 18.62% compared to ¥220,289,718.39 in the same period last year[5] - Net profit attributable to shareholders was ¥2,279,754.74, down 28.96% from ¥3,209,240.40 year-on-year[5] - Basic and diluted earnings per share decreased by 29.41% to ¥0.0036 from ¥0.0051 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 179,277,340.12, a decrease of 18.6% compared to CNY 220,289,718.39 in the same period last year[23] - Net profit for Q1 2024 increased to CNY 4,123,269.28, compared to CNY 3,098,819.01 in Q1 2023, representing a growth of 32.9%[24] - Total comprehensive income for the first quarter was CNY 4,123,269.28, an increase from CNY 3,098,819.01 in the previous year[25] - Net income attributable to the parent company was CNY 2,279,754.74, down from CNY 3,209,240.40 year-over-year[25] - Basic and diluted earnings per share were both CNY 0.0036, compared to CNY 0.0051 in the same period last year[25] Cash Flow and Investments - The net cash flow from operating activities improved significantly, reaching -¥25,035,659.98, an increase of 79.13% compared to -¥119,963,874.13 in the previous year[5] - Cash inflow from operating activities totaled CNY 228,953,557.57, up from CNY 140,610,550.26 in the previous year[26] - Net cash flow from operating activities was negative CNY 25,035,659.98, an improvement from negative CNY 119,963,874.13 year-over-year[27] - Cash outflow from investing activities was CNY 37,756,102.86, compared to CNY 46,911,431.72 in the previous year[27] - Net cash flow from financing activities was CNY 49,109,880.09, down from CNY 228,454,523.64 year-over-year[27] - The company's cash and cash equivalents at the end of the period amount to RMB 207,256,110.60, down from RMB 211,179,872.15 at the beginning of the period[20] - The company's cash and cash equivalents were CNY 909,237,950.98, down from CNY 940,337,254.90, a decline of 3.3%[22] - The ending balance of cash and cash equivalents was CNY 103,281,717.07, slightly down from CNY 104,408,862.55 in the previous year[27] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥2,131,733,749.69, a slight decrease of 0.08% from ¥2,133,478,855.05 at the end of the previous year[5] - Total assets as of Q1 2024 were CNY 2,131,733,749.69, a slight decrease from CNY 2,133,478,855.05 in the previous quarter[22] - Total liabilities decreased to CNY 1,051,102,845.71 from CNY 1,057,086,387.08, reflecting a reduction of 0.6%[22] - The company reported a decrease in short-term borrowings to CNY 257,000,000.00 from CNY 276,352,883.33, a reduction of 7%[22] - The total equity attributable to shareholders increased to CNY 1,035,589,577.21 from CNY 1,033,194,655.74, a growth of 0.2%[22] Operational Changes - Operating costs decreased by 38.83% to ¥99,694,789.08, primarily due to changes in sales structure and reduced output in steel structure projects[11] - The company experienced a 67.59% increase in selling expenses to ¥51,295,739.42, attributed to the acquisition of Tibet Kangyu[11] - Cash paid for purchasing goods and services decreased by 31.52% to ¥96,506,277.15, reflecting reduced payments for engineering materials[12] - The company reported a 235.56% increase in cash paid for debt repayment, totaling ¥109,779,500.00, indicating a rise in bank loan repayments[12] Shareholder Information - The total number of common shareholders at the end of the reporting period is 39,590[15] - Sichuan Huashen Group holds 17.74% of shares, with 111,431,281 shares pledged[15] - Chengdu Yuanhong Biotechnology Co., Ltd. plans to increase its stake in the company by investing between RMB 30 million and RMB 60 million, starting from February 6, 2024[17] - Chengdu Yuanhong increased its shareholding by 6,280,000 shares, representing 1% of the total share capital[17] Other Information - The company’s board secretary resigned on March 18, 2024, and the vice president will temporarily assume the role[18] - The company has not undergone an audit for the first quarter report[28] - The company is implementing new accounting standards starting in 2024[28]

成都市高新区交子大道 333 号中海国际中心 E 座 602 室 电话：028-65585333 传真：028-66266533 邮编：610041 北京国枫（成都）律师事务所 关于成都华神科技集团股份有限公司 致：成都华神科技集团股份有限公司（贵公司） 北京国枫（成都）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师 出席并见证贵公司 2024 年第二次临时股东大会（以下简称"本次会议"）。 2024 年第二次临时股东大会的 法律意见书 国枫律股字[2024]D0005 号 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简 称"《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券 法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证 券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《成都华神科技 集团股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开 程序、召集人资格、出席会议人员资格、会议表决程序及表 ...

证券代码：000790 证券简称：华神科技 公告编号：2024-014 成都华神科技集团股份有限公司 2024年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开和出席的情况 1、会议召开的时间： （1）现场会议时间：2024 年 4 月 15 日（星期一）下午 14:30 公司总股份 628,142,564 股，通过现场和网络投票的股东 23 人，代表股份 120,392,810 股，占上市公司总股份的 19.1665%。其中：通过现场投票的股东 1 人，代表股份 111,431,281 股，占上市公司总股份的 17.7398%；通过网络投票的 股东 22 人，代表股份 8,961,529 股，占上市公司总股份的 1.4267%。 中小股东出席的总体情况：通过现场和网络投票的中小股东 21 人，代表股 份 2,681,529 股，占上市公司总股份的 0.4269%。其中：通过现场投票的中小股 东 0 人，代表股份 0 股，占上市公司总股份的 0.0000%；通过网络投票的中小股 东 21 人，代表股份 2,681,529 ...

证券代码：000790 证券简称：华神科技 公告编号：2024-013 成都华神科技集团股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《企业会计准则第16号-政府补助》的规定，与资产相关的政府补助， 是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益相 关的政府补助，是指除与资产相关的政府补助之外的政府补助。上述政府补助 系与收益相关。 2．补助的确认和计量 根据《企业会计准则第16号-政府补助》的相关规定，公司获得的上述政府 补助均属于与收益相关的政府补助，且与公司日常经营活动相关，公司将计入 "其他收益"。 3．补助对上市公司的影响 上述政府补助1,123.12万元列入其他收益，预计对公司2023年度及2024年度 的利润总额产生正面影响，具体的会计处理及其对公司相关财务数据的影响将 以会计师事务所年度审计确认后的结果为准，敬请广大投资者注意投资风险。 三、备查文件 一、获取补助的基本情况 2024 年 3 月 29 日，成都华神科技集团股份有限公司（以下简称"公司"）之 控股子公司西藏康域药业有 ...

证券代码：000790 证券简称：华神科技 公告编号：2024-010 因经营发展需要，为保证全资子公司四川华神钢构有限责任公司（简称 "华神钢构"）、控股子公司山东凌凯药业有限公司（简称"山东凌凯"）的 现金流量充足，华神钢构、山东凌凯拟向银行申请总额为 22000 万元的综合授 信，公司提供不超过 17600 万元的连带责任保证担保。具体内容详见公司在巨潮 资讯网同日披露的相关公告。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案还需提交股东大会审议。 成都华神科技集团股份有限公司 第十三届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都华神科技集团股份有限公司（简称"公司"）第十三届董事会第十次 会议于2024年3月29日以现场与通讯表决相结合的方式在公司会议室召开。本次 会议通知于2024年3月26日发出，本次会议应出席董事9人，实际出席董事9人。 会议由公司董事长黄明良先生主持，公司监事、高级管理人员列席了会议。本 次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和《公 ...

证券代码：000790 证券简称：华神科技 公告编号：2024-012 成都华神科技集团股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本次股东大会的召集、召开符合有关法律、行政法规、部门规章、规范性 文件和《公司章程》的规定。 4、会议召开时间： （1）现场会议时间：2024年4月15日（星期一）下午14:30 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 经成都华神科技集团股份有限公司（以下简称"公司"）第十三届董事会第 十次会议审议决定，公司将以现场表决与网络投票相结合的方式召开2024年第 二次临时股东大会。现将有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次 成都华神科技集团股份有限公司2024年第二次临时股东大会 2、股东大会的召集人 公司董事会 3、会议召开的合法、合规性 （2）网络投票时间：2024年4月15日 其中：通过深圳证券交易所交易系统进行网络投票的时间为：2024年4月15 日9:15-9:25,9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票 的时间为：2024年4月15 ...

证券代码：000790 证券简称：华神科技 公告编号：2024-011 成都华神科技集团股份有限公司 关于子公司向银行申请授信并提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 超过 15000 万元的综合授信，其中敞口额度 10000 万元为固定资产贷款，期限 4 年，由山 东凌凯名下位于潍坊滨海经济技术开发区辽河西五街以南、临港路以西的土地使用权和项 目建设形成的在建工程以及未用于融资租赁的可抵押设备提供抵押担保，华神科技提供不 超过 10000 万元的连带责任保证担保。敞口额度 5000 万元为短期综合授信（信贷业务品 种包括但不限于短期流动资金贷款、敞口不高于票面金额 50%的银行承兑汇票），期限 1 年，由华神科技提供不超过 5000 万元的连带责任保证担保。 （二）华神钢构向金融机构申请授信（含担保）具体情况 华神钢构拟向徽商银行股份有限公司成都金沙支行（简称"徽商银行"）申请授信总 额不超过 7000 万元的综合授信，其中敞口额度 2000 万元，期限 2 年，由华神科技提供不 超过 2600 万元的连带责任保证担保。 以上授信最终 ...

刁海雷先生在担任公司董事会秘书期间勤勉尽责，恪尽职守，为公司的发展 做出了重要贡献。公司董事会对刁海雷先生任职期间为公司发展所做出的努力和 贡献表示衷心感谢！ 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 成都华神科技集团股份有限公司（以下简称"公司"）董事会于近日收到公 司董事会秘书刁海雷先生提交的书面辞职报告。因个人原因，刁海雷先生申请辞 去公司董事会秘书职务，辞职申请自送达公司董事会之日起生效。刁海雷先生辞 去公司董事会秘书职务后，不再担任公司及子公司任何职务，其辞职不会影响公 司相关工作的正常运行。 截至本公告披露之日，刁海雷先生通过限制性股票激励计划持有本公司股份 120,000 股。其所持公司股份将继续严格按照《公司法》《上市公司股权激励管 理办法》等法律法规及公司股权激励相关规定进行管理。 根据《公司法》《深圳证券交易所股票上市规则》及《公司章程》等有关规 定，在公司董事会秘书空缺期间，由公司副总裁、财务总监李俊先生代为履行董 事会秘书职责，公司将尽快完成董事会秘书的聘任工作。 证券代码：000790 证券简称：华神科技 公告编号：2024-0 ...

关于公司间接控股股东增持股份达到1%的公告 证券代码：000790 证券简称：华神科技 公告编号：2024-008 成都华神科技集团股份有限公司 特此公告。 成都远泓生物科技有限公司保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 成都华神科技集团股份有限公司 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 董 事 会 成都华神科技集团股份有限公司（以下简称"公司"）于 2024 年 2月 7 日收 到公司间接控股股东成都远泓生物科技有限公司（以下简称"成都远泓"）提交 的《关于增持股份情况的告知函》。 2024 年 2 月 7 日，成都远泓通过证券交易 所集中交易方式合计增持公司股份6,280,000 股，占公司总股本的 1%，现将有 关情况披露如下： 二〇二四年二月八日 | 1．基本情况 | | | | | --- | --- | --- | --- | | 信息披露义务人 | 成都远泓生物科技有限公司 | | | | 住所 | 成都高新区益州大道中段555号1栋1单元26楼2606号 | | | | 权益变动时间 | 2024年2月7日 | | | ...